Key result
Genetic polymorphisms in MME (OR 1.795), BDKRB2 (OR 1.609), PTGER3 (OR 0.565), and ACE genes are significantly associated with susceptibility to ACE inhibitor-induced cough.
Why the study?
Are specific genetic polymorphisms associated with susceptibility to ACEi-induced cough in hypertensive patients?
Population
Hypertensive patients treated with angiotensin-converting enzyme inhibitors (ACEi)
Comparison
Presence of specific genetic polymorphisms vs Absence of these genetic polymorphisms
Design
Other
Authors
Loading...
May support risk stratification for ACEi cough; leaves open prospective validation before clinical genetic testing.
Observational
Are specific genetic polymorphisms associated with susceptibility to ACEi-induced cough in hypertensive patients?
Odds Ratio: 1.795
p-value: p=0.002
Specific genetic polymorphisms in MME, BDKRB2, PTGER3, and ACE genes, as well as epistatic interactions, significantly modify the risk of developing ACEi-induced cough.
Grilo et al. (2010) conducted an observational in ACE inhibitor-induced cough in hypertension. Genetic polymorphisms (MME, BDKRB2, PTGER3, ACE) was evaluated on ACEi-induced cough (OR 1.795, p=0.002). Genetic polymorphisms in MME (OR 1.795), BDKRB2 (OR 1.609), PTGER3 (OR 0.565), and ACE genes are significantly associated with susceptibility to ACE inhibitor-induced cough.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: